Page 134 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Chapter 6a
Table 1. Baseline Patient Characteristics.
Characteristic
Number of patients
Age at diagnosis (y)
Median (range) ≤60
>60
Sex
Male Female
WHO performance status
0
1
2 Unknown
Ann Arbor Stage
II III IV
LDH
Normal >Normal
aaIPI
Low Low-intermediate High-intermediate High
B symptoms
No Yes
Treatment Arm
R-CHOP14 RR-CHOP14
Diagnosis-treatment interval (d)
Median(IQR) Range
Baseline PET
I-PET4
513 (100)
65 (23-80) 172 (33.5) 341 (66.5)
267 (52.0) 246 (48.0)
266 (51.9) 183 (35.7) 61 (11.9) 3 (0.6)
97 (18.9) 163 (31.8) 253 (49.3)
171 (33.3) 342 (66.7)
36 (7.0) 177 (34.5) 255 (49.7) 45 (8.8)
297 (57.9) 216 (42.1)
252 (49.1) 261 (50.9)
20 (13-28) 1-112
384 (74.9)
∆SUVmax
367 (100)
65 (23-80) 123 (33.5) 244 (66.5)
192 (52.3) 175 (47.7)
201 (54.8) 118 (32.2) 46 (12.5) 2 (0.5)
61 (16.6) 113 (30.8) 193 (52.6)
124 (33.8) 243 (66.2)
23 (6.3) 127 (34.6) 181 (49.3) 36 (9.8)
211 (57.5) 156 (42.5)
186 (50.7) 181 (49.3)
20 (13-28) 1-81
367 (100)
MTV
296 (100)
65 (23-80) 96 (32.4) 200 (67.6)
150 (50.7) 146 (49.3)
165 (55.7) 92 (31.1) 37 (12.5) 2 (0.7)
52 (17.6) 90 (30.4) 154 (52.0)
98 (33.1) 198 (66.9)
21 (7.1) 97 (32.8) 150 (50.7) 28 (9.5)
169 (57.1) 127 (42.9)
150 (50.7) 146 (49.3)
20 (14-28) 1-81
296 (100)
IQR=interquartile range; LDH=lactate dehydrogenase; WHO=world health organization. Data are number followed by percentage in parentheses, unless indicated otherwise.
I-PET4 analyses
Of 513 I-PET4 scans, 113 (22%) were rated as PET-positive (no complete metabolic response). Dichotomization of I-PET4 results into DS4-5 (positive) versus DS1-3 (negative) yielded a 2-y PFS of 61% (95%CI, 52%-70%) for I-PET4- positive patients and 84% (95%CI, 81%-88%) for I-PET4-negative patients (P <0.001), with a corresponding univariate HR of 3.1 (95%CI, 2.1-4.5; Table 2; Fig. 2a). Among the patients who experienced a relapse, the median time to relapse for I-PET4-positives was 8.1 mo (interquartile range, 4.4-23.2), versus 18.1 mo
132